Candida albicans and non-Candida albicans fungemia in an institutional hospital during a decade

Medical Mycology

Volumn 51, Issue 1, 2013, Pages 33-37

  Parmeland, Laurence ^a   Gazon, Mathieu ^a   Guerin, Claude ^a   Argaud, Laurent ^b   Lehot, Jean Jacques ^c   Bastien, Olivier ^c   Allaouchiche, Bernard ^b   Michallet, Mauricette ^d   Picot, Stephane ^a,e   Bienvenu, Anne Lise ^a,e   Andre, S ^f   Barth, X ^f   Baulieux, J ^f   Bayle, F ^f   Boulez, J C ^f   Bourdin, G ^f   Carret, J P ^f   Chidiac, C ^f   Claris, O ^f   Confavreux, C ^f   Cordier, J F ^f   Debord, S ^f   Delannoy, B ^f   Dubreuil, C ^f   Durieu, I ^f   Etienne, J ^f   Feugier, P ^f   Finet, G ^f   Flandrois, J P ^f   Floret, D ^f   Fouque, D ^f   Lachaux, A ^f   Leray, V ^f   Martin, X ^f   Ninet, J ^f   Pandin, C ^f   Persat, F ^f   Peyramond, D ^f   Piriou, V ^f   Ponchon, T ^f   Richard, J C ^f   Ruffion, A ^f   Souquet, P J ^f   Tigaud, S ^f   Trouillas, P J ^f   Vandenesch, F ^f   Viale, J P ^f   more..

^a CROIX ROUSSE HOSPITAL   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

^c LOUIS PRADEL HOSPITAL   (France)

^d CENTRE HOSPITALIER LYON SUD   (France)

^e CPE LYON   (France)

^f HOSPICES CIVILS DE LYON   (France)

Author keywords

Antifungals; Candidemia; Epidemiology; Prospective study; Resistance

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; CASPOFUNGIN; FLUCONAZOLE; VORICONAZOLE;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA FAMATA; CANDIDA GLABRATA; CANDIDA INCONSPICUA; CANDIDA KRUSEI; CANDIDA NIVARIENSIS; CANDIDA PARAPSILOSIS; CANDIDA SAKE; CANDIDA TROPICALIS; CANDIDEMIA; CHILD; CLAVISPORA LUSITANIAE; FEMALE; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; KLUYVEROMYCES MARXIANUS; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PICHIA GUILLIERMONDII; PRESCHOOL CHILD; PROSPECTIVE STUDY; SCHOOL CHILD; YARROWIA LIPOLYTICA;

EID: 84870938383     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693786.2012.686673     Document Type: Article

References (20)

1. Vincent JL, Rello J, Marshall J, e t al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302: 2323-2329.
2. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-535.
3. Leroy O, Mira JP, Montravers P, Gangneux JP, Lortholary O. Comparison of albicans vs. non- albicans candidemia in French intensive care units. Crit Care 2010; 14: R98.
4. Garnacho-Montero J, Diaz-Martin A, Garcia-Cabrera E, e t al. Risk factors for fl uconazole-resistant candidemia. Antimicrob Agents Chemother 2010; 54: 3149-3154.
5. Lortholary O, Desnos-Ollivier M, Sitbon K, et al. Recent exposure to caspofungin or fl uconazole infl uences the epidemiology of candi demia: A prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother 2011; 55: 532-538.
6. Slavin MA, Sorrell TC, Marriott D, e t al. Candidaemia in adult cancer patients: Risks for fl uconazole-resistant isolates and death. J Antimicrob Chemother 2010; 65: 1042- 1051.
7. Martin D, Persat F, Piens MA, Picot S. Candida species distribution in bloodstream cultures in Lyon, France, 1998-2001. Eur J Clin Microbiol Infect Dis 2005; 24: 329-333.
8. Pfaller MA, Diekema DJ, Andes D, and the CLSI Subcommittee for Antifungal Testing. Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specifi c interpretive criteria. Drug Resist Updat 2011; 14: 164- 176.
9. Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A, Sheehan D and CLSI Subcommittee for Antifungal Susceptibility Testing. Wild-type MIC distributions, epidemiological cutoff values and species-specifi c clinical breakpoints for fl uconazole and Candida: Time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat 2010; 13: 180-195.
10. Pfaller MA, Andes D, Arendrup MC, et al. Clinical breakpoints for voriconazole and Candida spp. revisited: Review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specifi c interpretive criteria. Diagn Microbiol Infect Dis 2011; 70: 330-343.
11. Arendrup MC. Epidemiology of invasive candidiasis. C urr Opin Crit Care 2010; 16: 445-452.
12. Falagas ME, Roussos N, Vardakas KZ. Relative frequency of a lbicans and the various non- albicans Candida spp among candidemia isolates from inpatients in various parts of the world: A systematic review. Int J Infect Dis 2010; 14: E954- 966.
13. Lewis RE. Overview of the changing epidemiology of candidemia. Curr Med Res Opin 2009; 25: 1732-1740.
14. Miceli MH, Diaz JA, Lee SA. Emerging opportunistic yeast infections. Lancet Infect Dis 2011; 11: 142-151.
15. Horn DL, Neofytos D, Anaissie EJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: Data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009; 48: 1695-1703.
16. Hassan I, Powell G, Sidhu M, Hart WM, Denning DW. Excess mortality, length of stay and cost attributable to candidaemia. J Infect 2009; 59: 360-365.
17. Bassetti M, Mikulska M, Viscoli C. Bench-to-bedside review: Therapeutic management of invasive candidiasis in the intensive care unit. Crit Care 2010; 14: 244.
18. Guery BP, Arendrup MC, Auzinger G, et al. Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I. Epidemiology and diagnosis. Intensive Care Med 2009; 35: 55-62.
19. Taur Y, Cohen N, Dubnow S, Paskovaty A, Seo SK. Effect of antifungal therapy timing on mortality in cancer patients with candidemia. Antimicrob Agents Chemother 2010; 54: 184-190.
20. Mokaddas E, Khan ZU, Ahmad S, Nampoory MR, Burhamah M. Value of (1 - 3)- ® -d-glucan, Candida mannan and Candida DNA detection in the diagnosis of candidaemia. Clin Microbiol Infect 2011; 17: 1549-1553.